Biopharmaceutical company Rock Holding Corporation (Nasdaq:SRRK) said on Tuesday that it plans to issue and sell USD150m shares of its common stock an underwritten public offering.

The company intends to provide the underwriters with a 30-day option to purchase up to an additional USD22,500,000 of shares of common stock offered in the public offering.

Net proceeds may be used by the company to advance SRK-015 in Spinal Muscular Atrophy, including costs associated with preparing for and executing clinical trials, including a Phase 3 clinical trial, SRK-181 in cancer immunotherapy, development of its preclinical and discovery programs, as well as for working capital and other general corporate purposes.

Subject to market and other conditions, there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms. JP Morgan Securities LLC, Jefferies LLC and Credit Suisse Securities (USA) LLC are the joint book-running managers.